Cencora, Inc. (COR) Stock Price: $281.67+0.19 (+0.07%)
At close: Jun 12, 2026, 4:00 PM ET
The closing share price for Cencora, Inc. (COR) stock was $281.67 for Friday, June 12, 2026, up 0.07% on the day.
Longer view (total return, dividends reinvested): past 12 months -3.8% · 3-year avg +17.2%/yr · 5-year avg +19.9%/yr
COR Price Chart
COR is featured in
COR Key Metrics
See All MetricsCOR Earnings Preview
Next Earnings Date
Aug 5, 2026
53 days away
EPS Estimate
4.37
Revenue Est.
$84.36B
Last Quarter Results
EPS
$4.75
vs Estimate
$4.73
Revenue
$78.36B
vs Estimate
$81.09B
COR Analyst Ratings
Consensus Rating
Based on 12 analysts
Average Price Target
$350.58
+24.5% upside
Low
$280.00
Current
$281.67
High
$412.00
COR Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q4 2027 | $5.10 | $5.21 | $5.31 | 6 |
| Q1 2028 | $5.49 | $5.62 | $5.72 | 4 |
| Q2 2028 | $5.52 | $5.64 | $5.75 | 6 |
| Q3 2028 | $5.84 | $5.97 | $6.08 | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $19.30 | $19.81 | $20.25 | 8 |
| FY 2028 | $20.06 | $21.98 | $24.54 | 3 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q4 2027 | $93.06B | $94.65B | $96.05B | 3 |
| Q1 2028 | $85.84B | $87.31B | $88.60B | 2 |
| Q2 2028 | $93.36B | $94.95B | $96.35B | 2 |
| Q3 2028 | $97.98B | $99.66B | $101.13B | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $351.29B | $356.81B | $365.14B | 9 |
| FY 2028 | $377.25B | $378.79B | $380.34B | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
Related Stocks
HealthcareCOR Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1COR | $54.80B | $281.67 | +0.07% | -3.81% | +19.86% | +17.22% | — |
| 2BDX | $52.98B | $146.24 | -0.75% | +9.25% | -2.99% | +2.80% | vs COR |
| 3REGN | $63.06B | $612.14 | +0.11% | +17.95% | +3.26% | +5.19% | vs COR |
| 4HUM | $45.53B | $379.22 | +2.86% | +64.02% | -1.01% | +8.24% | vs COR |
| 5IDXX | $44.24B | $560.88 | +0.53% | +6.45% | -0.82% | +20.22% | vs COR |
| 6A | $36.67B | $129.84 | +0.22% | +9.88% | -1.34% | +11.94% | vs COR |
COR Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch